Apersys AG Analysis
What is Apersys AG?
Apersys AG develops a perfusion system to preserve and restore livers once considered unsuitable for transplantation. The technology, backed by preclinical and first-in-human data, aims to expand transplant availability by addressing organ shortages. The company combines expertise from liver transplantation science with medical device entrepreneurship.
Location
Zurich, Switzerland
Employees
11-50
Founded
2024
Funding Status
Series A
Product Features & Capabilities
- Perfusion system to preserve and restore livers once deemed unfit for transplant
Use Cases
Preserve livers with severe fatty degeneration; Restore function in livers previously rejected for transplant; Enable transplant for patients with no viable donor organs; Support preclinical research in liver regeneration; Treat patients with end-stage liver disease
Other Considerations
Stemming from Liver4Life project at Wyss Zurich Translational Center; Supported by ETH Zurich and UZH; Preclinical and first-in-human data available; Founded in 2024
See something that needs updating? Suggest edits to this profile.